PASG Passage BIO Inc

Price (delayed)

$0.8296

Market cap

$51.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.53

Enterprise value

$40.84M

Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with ...

Highlights
The EPS has grown by 35% YoY and by 18% from the previous quarter
The net income is up by 34% year-on-year and by 17% since the previous quarter
The quick ratio has increased by 16% QoQ but it has decreased by 16% YoY
The equity has contracted by 38% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of PASG
Market
Shares outstanding
61.64M
Market cap
$51.14M
Enterprise value
$40.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$84.44M
EBITDA
-$80.89M
Free cash flow
-$74.87M
Per share
EPS
-$1.53
Free cash flow per share
-$1.33
Book value per share
$1.89
Revenue per share
$0
TBVPS
$2.5
Balance sheet
Total assets
$140.53M
Total liabilities
$35.65M
Debt
$26.48M
Equity
$104.88M
Working capital
$95.45M
Liquidity
Debt to equity
0.25
Current ratio
8.43
Quick ratio
8.14
Net debt/EBITDA
0.13
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.6%
Return on equity
-68.5%
Return on invested capital
-59.4%
Return on capital employed
-66.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PASG stock price

How has the Passage BIO stock price performed over time
Intraday
-4.64%
1 week
-12.67%
1 month
-8.84%
1 year
-16.47%
YTD
-17.86%
QTD
5.01%

Financial performance

How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$84.44M
Net income
-$84.44M
Gross margin
N/A
Net margin
N/A
The operating income is up by 34% year-on-year and by 17% since the previous quarter
The net income is up by 34% year-on-year and by 17% since the previous quarter

Growth

What is Passage BIO's growth rate over time

Valuation

What is Passage BIO stock price valuation
P/E
N/A
P/B
0.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 35% YoY and by 18% from the previous quarter
The stock's price to book (P/B) is 62% less than its 5-year quarterly average of 1.2 and 8% less than its last 4 quarters average of 0.5
The equity has contracted by 38% YoY and by 6% from the previous quarter

Efficiency

How efficient is Passage BIO business performance
The company's return on equity fell by 13% YoY but it rose by 6% QoQ
PASG's return on assets is up by 8% since the previous quarter but it is down by 3.6% year-on-year
The ROIC has grown by 7% from the previous quarter and by 3.6% YoY

Dividends

What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PASG.

Financial health

How did Passage BIO financials performed over time
Passage BIO's total assets has decreased by 34% YoY and by 7% from the previous quarter
Passage BIO's current ratio has increased by 17% from the previous quarter but it has decreased by 15% YoY
The debt is 75% less than the equity
The debt to equity has soared by 56% YoY and by 4.2% from the previous quarter
The equity has contracted by 38% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.